Iterum Therapeutics shares surge 10.81% intraday after director Dunne buys $2,191 in shares.

Iterum Therapeutics surged 10.81% intraday following a significant insider purchase by director Michael W. Dunne, who acquired 6,000 shares for $2,191 on November 18, 2025. This transaction, disclosed via a Form 4 filing, signaled confidence in the company’s outlook, likely boosting investor sentiment. While the firm also reported a wider-than-expected Q3 2025 loss of $0.16 per share, the timing of the insider buy—occurring after the earnings release—suggests it overrode short-term bearish momentum. The stock’s sharp intraday rally aligns with the perceived positive signal from Dunne’s purchase, overshadowing recent negative earnings results and positioning the move as a reaction to insider activity rather than broader fundamentals.